NICE scopes Alexza's Adasuve for schizophrenia
This article was originally published in Scrip
Executive Summary
Alexza Pharmaceuticals' schizophrenia treatment Adasuve (loxapine) will shortly be up for review by NICE, the health technology appraisal institute for England and Wales. The institute has put the draft version of the scope of the review out for consultation.